Does Rallies show Form 4 insider transactions for CMPX?

Yes. Rallies tracks CMPX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CMPX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CMPX. It does not provide personalized investment advice.

CMPX (Compass Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Compass Therapeutics, Inc. Common Stock (CMPX) is a publicly traded Healthcare sector company. As of May 21, 2026, CMPX trades at $1.85 with a market cap of $329.56M and a P/E ratio of -4.46. CMPX moved +3.87% today. Year to date, CMPX is -62.12%; over the trailing twelve months it is -10.00%. Its 52-week range spans $1.27 to $6.88. Analyst consensus is strong buy with an average price target of $10.11. Rallies surfaces CMPX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CMPX stock inside the company?

Recent CMPX insider activity includes Lerner Neil bought 15.00K, Anderman Jonathan bought 25.00K, Schuetz Thomas J. bought 10.00K, GORDON CARL L sold 3.57M, and ORBIMED ADVISORS LLC sold 3.57M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CMPX Key Metrics

Key financial metrics for CMPX
Metric	Value
Price	$1.85
Market Cap	$329.56M
P/E Ratio	-4.46
EPS	$-0.42
Dividend Yield	0.00%
52-Week High	$6.88
52-Week Low	$1.27
Volume	3.40M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-66.49M
Gross Margin	0.00%

Recent CMPX Insider Trades

Lerner Neil bought 15.00K (~$28.35K) on Apr 29, 2026.
Anderman Jonathan bought 25.00K (~$47.25K) on Apr 29, 2026.
Schuetz Thomas J. bought 10.00K (~$21.10K) on May 27, 2025.
GORDON CARL L sold 3.57M (~$5.68M) on Apr 9, 2025.
ORBIMED ADVISORS LLC sold 3.57M (~$5.68M) on Apr 9, 2025.

Latest CMPX News

Compass Therapeutics Phase 2/3 Tovecimig Achieves 17.1% ORR, Holds $195M Cash — May 5, 2026
Compass Therapeutics Reports 56% PFS Risk Reduction, 17.1% ORR in Biliary Cancer Study — Apr 27, 2026

CMPX Analyst Consensus

12 analysts cover CMPX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.11.

Common questions about CMPX

Who is trading CMPX stock inside the company?: Recent CMPX insider activity includes Lerner Neil bought 15.00K, Anderman Jonathan bought 25.00K, Schuetz Thomas J. bought 10.00K, GORDON CARL L sold 3.57M, and ORBIMED ADVISORS LLC sold 3.57M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CMPX?: Yes. Rallies tracks CMPX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CMPX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CMPX. It does not provide personalized investment advice.